Syneron Added to Russell Indexes
29 Junio 2010 - 11:00AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today that it has been added to the
Russell 3000®, Russell 2000® and Russell Microcap® Indexes,
effective June 25, 2010 after the close of the U.S. markets.
Louis P. Scafuri, Chief Executive Officer, commented, "We are
pleased that Syneron is now included in the Russell Indexes,
broadening our exposure to the institutional and retail investment
communities. The addition comes at an important point in the
Company's growth trajectory, as we work to leverage the benefits of
our merger with Candela, increase adoption of our recently launched
product platforms, and advance our pipeline of innovative aesthetic
products to address the changing needs of both physicians and
patients."
The annual reconstitution of Russell's U.S. indexes captures the
4,000 largest U.S. stocks as of the last trading day in May,
ranking them by total market capitalization. The Russell 3000
includes the largest 3,000 of these stocks and automatic inclusion
in the large-cap Russell 1000 Index or small-cap Russell 2000
Index, as well as the appropriate growth and value style indexes.
The Russell 3000 also serves as the U.S. component to the Russell
Global Index, which Russell launched in 2007. The Russell Microcap
Index is comprised of the smallest 1,000 stocks in the Russell 2000
Index plus the next smallest 1,000 stocks. Membership in the
Russell Indexes, which remains in place for one year, is determined
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. An industry-leading $3.9
trillion in assets currently are benchmarked to them.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global
aesthetic device company with a comprehensive product portfolio and
a global distribution footprint. The Company's technology enable
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The company markets and services and supports its products in 86
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide. Additional information can be found at
www.syneron.com.
Contacts: Fabian Tenenbaum Chief Financial Officer + 972
73 244 2283 Email: Email Contact Nick Laudico / Zack Kubow The Ruth
Group 646-536-7030 / 7020 Email: Email Contact Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024